<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Chronic Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Chronic Dis</journal-id>
<journal-id journal-id-type="publisher-id">IJCD</journal-id>
<journal-title-group>
<journal-title>International Journal of Chronic Diseases</journal-title>
</journal-title-group>
<issn pub-type="ppub">2356-6981</issn>
<issn pub-type="epub">2314-5749</issn>
<publisher>
<publisher-name>Hindawi</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32099839</article-id>
<article-id pub-id-type="pmc">7038435</article-id>
<article-id pub-id-type="doi">10.1155/2020/5950813</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Conceptualization of Heterogeneity of Chronic Diseases and Atherosclerosis as a Pathway to Precision Medicine: Endophenotype, Endotype, and Residual Cardiovascular Risk</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-5902-3803</contrib-id>
<name>
<surname>Genkel</surname>
<given-names>Vadim V.</given-names>
</name>
<email>henkel-07@mail.ru</email>
<xref ref-type="aff" rid="I1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shaposhnik</surname>
<given-names>Igor I.</given-names>
</name>
<xref ref-type="aff" rid="I1"></xref>
</contrib>
</contrib-group>
<aff id="I1">Department of Internal Medicine, Federal State Budgetary Educational Institution of Higher Education “South-Ural State Medical University” of the Ministry of Healthcare of the Russian Federation, Vorovskogo St. 64, 454092 Chelyabinsk, Russia</aff>
<author-notes>
<fn fn-type="other">
<p>Academic Editor: Tadeusz Robak</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>12</day>
<month>2</month>
<year>2020</year>
</pub-date>
<volume>2020</volume>
<elocation-id>5950813</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Vadim V. Genkel and Igor I. Shaposhnik.</copyright-statement>
<copyright-year>2020</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>The article discusses modern approaches to the conceptualization of pathogenetic heterogeneity in various branches of medical science. The concepts of endophenotype, endotype, and residual cardiovascular risk and the scope of their application in internal medicine and cardiology are considered. Based on the latest results of studies of the genetic architecture of atherosclerosis, five endotypes of atherosclerosis have been proposed. Each of the presented endotypes represents one or another pathophysiological mechanism of atherogenesis, having an established genetic substrate, a characteristic panel of biomarkers, and a number of clinical features. Clinical implications and perspectives for the study of endotypes of atherosclerosis are briefly reviewed.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="sec1">
<title>1. The Concept of “Endophenotype”: Definition and Scope</title>
<p>In the classical definition of the term “endophenotype” (EP), given by Gottesman and Gould, EP is designated as “measurable components unseen by the unaided eye along the pathway between disease and distal genotype” [<xref ref-type="bibr" rid="B1">1</xref>]. Somewhat later in 2006, Gottesman and Gould identified six attributive signs of EP, and also defined the scope and purpose of this concept in neuroscience and psychiatry [<xref ref-type="bibr" rid="B2">2</xref>]. Currently, EP is defined as a genetically determined, measurable indicator with interindividual variability that is consistent with the variability of the target trait of a higher order (for example, normative function) [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>].</p>
<p>EP, occupying an intermediate position on the “genotype-EP-phenotype” pathway, can be represented at any level of analysis—anatomical, biochemical, neuropsychological, etc. Regardless, EP should reflect the genetic vulnerability of the individual and have an additional diagnostic value in comparison with the overt phenotype, since it represents a simpler and more accurate “marker” of the genetic basis of the disease [<xref ref-type="bibr" rid="B5">5</xref>]. However, the concept of EP is not synonymous with the concept of a biomarker. EP, unlike the biomarker, is genetically determined and is an integral part of the pathophysiological process (causally associated with it and occupying a place along the “genotype-phenotype” pathway underlying the disease [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>]). In other words, EP is always a biomarker, while the biomarker is not always EP [<xref ref-type="bibr" rid="B6">6</xref>].</p>
<p>In psychiatry and neuroscience, the concept of EP is used quite fruitfully. To date, various EPs of schizophrenia, autism spectrum disorders, bipolar affective disorder, etc. [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>] have been proposed and are being actively studied. For example, the following EP of schizophrenia can be distinguished at various levels: structural (reduction of the gray matter of the frontal and temporal lobes, reduction of the hippocampus); neurophysiological (eye-movement deficits); behavioral (introversion), etc. [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>].</p>
</sec>
<sec id="sec2">
<title>2. EP Concept in Internal Medicine</title>
<p>The concept of EP in internal medicine and related fields has now found limited application.</p>
<p>In a study by Shoda et al., three EPs of eosinophilic esophagitis were identified [<xref ref-type="bibr" rid="B12">12</xref>]. At this, each EP had a number of distinctive features at the genetic, immunological, morphological, endoscopic, and clinical levels. It is extremely important that the definition of EP in this case may contribute to the modification of the patient's therapy, since belonging to a particular EP determined the effectiveness of steroid therapy. Manjarrez-Orduño et al. identified the EP of systemic lupus erythematosus, which, according to the authors, is observed in 30-45% of patients [<xref ref-type="bibr" rid="B13">13</xref>]. This EP, designated as “cytotoxic,” is characterized by an increase in the content of CD8<sup>+</sup> of T-lymphocytes (CCR7-CD45R<sup>int-hi</sup> CD28<sup>−</sup>), producing various cytotoxic mediators (interferon-<italic>γ</italic>, perforin, and granzymes), and a high incidence of lupus nephritis.</p>
<p>In 2018, the report on asthma “After asthma: redefining airways diseases” was published in The Lancet [<xref ref-type="bibr" rid="B14">14</xref>]. In this paper, an attempt and a call were made for the deconstruction of “asthma” as a single nosological form for various endotypes, each of which have pathophysiological mechanisms with significant differences. The historically established umbrella term “asthma” leveled the heterogeneity of this clinical syndrome, artificially combining various processes into one group. Ignoring this fundamental heterogeneity determined, on the one hand, nonoptimal planning and interpretation of clinical studies of drugs, and on the other, hindered the development of a precision medicine approach to managing patients with asthma.</p>
<p>The authors examined the question of how the phenotypic (clinical) heterogeneity of asthma can be explained by different pathophysiological mechanisms or endotypes [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. It was noted that today it is not fully understood how far the phenotypic heterogeneity can affect our understanding of endotypes, since many phenotypic signs (for example, symptoms) can be caused by different mechanisms. As a result, the authors chose a reductionist approach, according to which, when identifying the EP of asthma, it is proposed to focus on traits that have different developmental mechanisms which can be recognized and diagnosed, and can also serve as a therapeutic target. Thus, the following EP of asthma has been proposed: airflow limitation, airway inflammation, airway infection, impaired airway defences, and altered cough reflex sensitivity and efficacy [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B16">16</xref>].</p>
<p>It should be noted that several endotypes of asthma have also been proposed earlier. Thus, depending on the nature of the inflammation pattern, neutrophilic and eosinophilic endotypes of asthma are distinguished [<xref ref-type="bibr" rid="B17">17</xref>]. Lötvall et al., in 2011, proposed the following endotypes of asthma: aspirin-associated asthma, allergic bronchopulmonary mycosis, allergic asthma, late-onset bronchial asthma (hypereosinophilic), and asthma of cross-country skiers [<xref ref-type="bibr" rid="B18">18</xref>]. Each of the endotypes proposed by Lötvall et al. have their own genetic basis, developmental mechanisms, characteristic biomarker profile, etc. [<xref ref-type="bibr" rid="B19">19</xref>].</p>
<p>It is worth noting that Pavord et al. and Lötvall et al. understand the concept of “endotype” somewhat differently, and accordingly, the endotypes of asthma they distinguish significantly differ. Endotypes of Pavord et al. are more consistent with the “classical” notions of EP, while the endotypes of Lötvall et al. occupy a more distal position along the “genotype-EP-phenotype” pathway, approaching directly the phenotype, that is, the disease. Moreover, these endotypes are essentially different forms of asthma (disease), and therefore, cannot fully meet the EP criteria given by Gould and Gottesman (EP must segregate with illness in the general population) [<xref ref-type="bibr" rid="B2">2</xref>]. Russell and Baillie define the endotype as “a subgroup within a population of patients who are distinguished by a shared disease process,” that is, with different leading mechanisms for the development of the disease [<xref ref-type="bibr" rid="B20">20</xref>]. This definition more closely matches the types that have been identified by Lötvall et al. In general, it is possible to define an endotype as a subtype of a disease defined by a distinctive leading pathophysiological mechanism [<xref ref-type="bibr" rid="B21">21</xref>].</p>
<p>Thus, at present, the conceptualization of the pathophysiological heterogeneity of the disease is carried out in terms of the “endophenotype” and “endotype.” Despite the differences in these approaches, each of them pursues the same utilitarian goals:
<list list-type="roman-lower"><list-item><p>A better understanding of endotypes of diseases will help optimize the planning and interpretation of clinical trials of new drugs and treatment methods. For example, in a clinical study of brodalumab blocking interleukin- (IL-) 17, which did not demonstrate a significant improvement in asthma, the proportion of patients with eosinophilic, rather than neutrophilic inflammation, for which brodalumab should be as effective as possible, was likely to be high [<xref ref-type="bibr" rid="B14">14</xref>]. Extrapolation of the results obtained from all endotypes of the disease does not contribute to the introduction of precision medicine and leads to suboptimal therapeutic regimens</p></list-item><list-item><p>Identification of endotypes of various diseases will give impetus for the initiation of a number of studies of new or already used drugs that have targeted the leading mechanisms in this particular endotype (for example, the study of various anti-inflammatory agents (methotrexate, colchicine) in patients with atherosclerotic cardiovascular diseases)</p></list-item><list-item><p>Identification of endotypes of diseases will optimize and personalize existing treatment regimens</p></list-item></list></p>
</sec>
<sec id="sec3">
<title>3. The Concept of Endotypes (EPs) in Cardiovascular Medicine and Atherosclerosis Research</title>
<p>In cardiovascular medicine, the concept of endotypes is used mainly in studies of heart failure (HF) and hypertension. Endotypes of HF are studied quite intensively in recent years [<xref ref-type="bibr" rid="B22">22</xref>]. Shah et al., through the method of machine learning, identified three endotypes of HF with preserved ejection fraction, significantly differing in clinical characteristics, features of the structure and function of the heart, hemodynamics, and the clinical trajectory of patients [<xref ref-type="bibr" rid="B23">23</xref>]. Tromp et al., using cluster analysis, identified six endotypes of HF, differing by clinical profile, biomarker profile, prognosis, and response to therapy (response to titration angiotensin-converting enzyme inhibitors and beta-blockers) [<xref ref-type="bibr" rid="B24">24</xref>]. Moreover, the actual classification of HF depending on the ejection fraction, fixed by clinical recommendations, also represents different biological phenotypes or endotypes of HF [<xref ref-type="bibr" rid="B25">25</xref>].</p>
<p>Hypertension is also understood for a long time as a heterogeneous group of subtypes with different etiologies and pathogeneses [<xref ref-type="bibr" rid="B26">26</xref>]. A number of researchers have identified various endotypes of hypertension: low-renin hypertension, salt-and-stress-sensitive hypertension, hypertension associated with obesity, etc. [<xref ref-type="bibr" rid="B27">27</xref>–<xref ref-type="bibr" rid="B29">29</xref>].</p>
<p>Atherosclerosis is a complex systemic disease, the development of which is determined by interactions of genetic, epigenetic, and environmental risk factors [<xref ref-type="bibr" rid="B30">30</xref>]. Adequate “endotyping” of atherosclerosis is impossible without an analysis of current studies of the genetic architecture of atherosclerosis and related diseases. For the first time, Farrer proposed to isolate endophenotypes of atherosclerosis as a possible approach to the study of the genetics of atherosclerosis, based on the dissection of various endotypes that have a strong genetic component [<xref ref-type="bibr" rid="B31">31</xref>]. Wyszynski and Farrer identified six endotypes of atherosclerosis: an increase in low-density lipoproteins (LDL), reduced high-density lipoproteins (HDL), an increase in lipoprotein(a) (Lp(a)), an increase in blood pressure, increased homocysteine, and metabolic syndrome [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>]. However, over the past years, an understanding of the genetics and pathophysiology of atherosclerosis has progressed significantly, which necessitates a revision of these endotypes.</p>
<p>According to large meta-analyses, 57 loci have been identified that are statistically significantly associated with the development of atherosclerosis and about 100 loci have been identified that are presumably associated with atherosclerosis [<xref ref-type="bibr" rid="B34">34</xref>]. Xi et al., after analyzing 45,304 publications, found references to 1,312 genes associated with atherosclerosis [<xref ref-type="bibr" rid="B35">35</xref>]. At least half of the known loci associated with the risk of developing coronary artery disease (CAD) demonstrate pleiotropy and are associated with the risk of other diseases or pathological processes [<xref ref-type="bibr" rid="B36">36</xref>].</p>
<p>The pathways associated with atherosclerosis and their genetic substrate are conserved during phylogenesis. Therefore, according to von Scheidt et al., among the 178 mechanisms associated with ischemic heart disease in humans, 53.2% are identical to those in mice [<xref ref-type="bibr" rid="B34">34</xref>]. The leading mechanisms common to humans and mice include disorders of lipid metabolism, hemostasis, and immune regulation. Xi et al., using gene ontology analysis, identified 50 pathophysiological pathways involved in the development of atherosclerosis [<xref ref-type="bibr" rid="B35">35</xref>]. The most highly overrepresented pathway went to the inflammation and Toll-like receptor signaling pathway [<xref ref-type="bibr" rid="B35">35</xref>].</p>
<p>According to the genome-wide association study (GWAS), among the currently identified loci associated with an increased risk of CAD and myocardial infarction, 24% are associated with lipid metabolism, 10% are associated with blood pressure, 2% are associated with carbohydrate metabolism, and 4% are associated simultaneously with several components [<xref ref-type="bibr" rid="B37">37</xref>]. 60% of the loci were not associated with the classic risk factors for atherosclerosis, and the interpretation of their role in atherogenesis is difficult.</p>
<p>It should be noted that when describing individual endotypes, much attention was paid to the results of studies with Mendelian randomization and GWAS. Of course, it is necessary to take into account the limitation of these types of studies, including the difficulty of identifying the nature of detectable associations between certain genetic variants and the trait of interest [<xref ref-type="bibr" rid="B38">38</xref>].</p>
<p>Nevertheless, the results of GWAS make it possible to identify regions of the genome and gene clusters that are important in the pathogenesis of polygenic diseases, which contributes to a better understanding of the mechanisms underlying certain diseases [<xref ref-type="bibr" rid="B39">39</xref>].</p>
<p>One of the promising areas that can combine the achievements of genetics and a whole range of fundamental and clinical disciplines is the multiomics approach, which should contribute to the identification of causal links between genetic variants and the molecular mechanisms of chronic multifactorial diseases [<xref ref-type="bibr" rid="B40">40</xref>].</p>
<p>Below, we consider the possible endotypes of atherosclerosis, selected on the basis of the leading pathophysiological mechanisms that have an established genetic substrate (the data are summarized in <xref ref-type="table" rid="tab1">Table 1</xref>).</p>
<sec id="sec3.1">
<title>3.1. Endotype, Associated with an Increase in LDL</title>
<sec id="sec3.1.1">
<title>3.1.1. Background</title>
<p>The key event in the development of atherosclerosis is subintimal accumulation of ApoB-containing lipoproteins, more than 90% of which are the LDL fraction. Today, there is no doubt that an increase in the concentration of LDL-cholesterol (namely, the cumulative burden of LDL-cholesterol) is the main causal factor in the development and progression of atherosclerosis [<xref ref-type="bibr" rid="B41">41</xref>]. The European Atherosclerosis Society Consensus Panel “Sensitivity of low-density lipoproteins cause atherosclerotic cardiovascular disease” discusses in detail evidence of the causal role of LDL in atherosclerosis [<xref ref-type="bibr" rid="B41">41</xref>].</p>
</sec>
<sec id="sec3.1.2">
<title>3.1.2. Genetics</title>
<p>Currently, various variants of genetic mutations that cause an increase in LDL and the development of atherosclerosis and related cardiovascular diseases are known: LDLR, PCSK9, APOE, APOB-100, SORT1, ANGPTL3, CELSR2, PSRC1, HMGCR, etc. [<xref ref-type="bibr" rid="B42">42</xref>–<xref ref-type="bibr" rid="B44">44</xref>]. In studies using the multiomics approach, the causal effects of the genetic variants SORT1 and HMGCR have been established [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>].</p>
</sec>
<sec id="sec3.1.3">
<title>3.1.3. Biomarkers</title>
<p>Biomarkers reflecting the cumulative burden of LDL-cholesterol include the following: total cholesterol, LDL-cholesterol, apolipoprotein B, apolipoprotein B-100, oxidized LDL (ox-LDLs), modified LDL, small dense LDL, and concentration of PCSK9.</p>
</sec>
<sec id="sec3.1.4">
<title>3.1.4. Clinical Features and Comorbid Conditions</title>
<p>This endotype is a “reference.” Hypercholesterolemia, caused by mutations in the LDLR gene, is a classic model of atherosclerosis in experimental studies.</p>
<p>In the last decade, the role of dyslipidemia in the development of cognitive impairment, including Alzheimer's disease, is actively discussed. There is evidence of a common genetic substrate of dyslipidemia and Alzheimer's disease (APOE, ABCA7, and SORT1) [<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>]. Also, according to Mendelian randomization studies, genetically determined high cholesterol is associated with an increased risk of developing breast cancer [<xref ref-type="bibr" rid="B49">49</xref>]. Moreover, hyperlipidemia may be associated with an increased risk of prostate and colon cancer [<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B51">51</xref>].</p>
</sec>
</sec>
<sec id="sec3.2">
<title>3.2. Endotype, Associated with an Increase in Lp(a)</title>
<sec id="sec3.2.1">
<title>3.2.1. Background</title>
<p>Elevated levels of Lp(a) predominantly cause damage to medium and large caliber arteries, as well as the aortic valve leaflets. There are three levels of evidence for the causal role of Lp(a) in the development of atherosclerosis: epidemiological studies, Mendelian randomization studies, and GWAS. The LPA gene contains elements that determine the inflammatory response with the participation of interleukin-6, which, together with other data, may indicate a close relationship between Lp(a) and inflammation in atherogenesis [<xref ref-type="bibr" rid="B52">52</xref>].</p>
</sec>
<sec id="sec3.2.2">
<title>3.2.2. Genetics</title>
<p>The level of circulating Lp(a) is mainly genetically determined by the LPA gene locus and is not significantly influenced by other genetic, dietary, or environmental factors [<xref ref-type="bibr" rid="B53">53</xref>]. Proteomix studies have identified networks of associated proteins that confirm the atherogenic effects of Lp(a) [<xref ref-type="bibr" rid="B54">54</xref>]. These networks include proteins involved in the inflammatory response (complement components), platelet aggregation (platelet activating factor), and fibrinolysis.</p>
</sec>
<sec id="sec3.2.3">
<title>3.2.3. Biomarkers</title>
<p>Biomarkers associated with an increase in Lp(a) include the following: Lp(a), apolipoprotein isoform (a), and antibodies to Lp(a) [<xref ref-type="bibr" rid="B55">55</xref>].</p>
</sec>
<sec id="sec3.2.4">
<title>3.2.4. Clinical Features and Comorbid Conditions</title>
<p>Patients with an increase in the level of Lp(a) associated with mutations in the LPA gene have an increased risk of the development and progression of aortic stenosis [<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>]. Also, an increase in the content of Lp(a) may be associated with an increased risk of venous thromboembolism [<xref ref-type="bibr" rid="B58">58</xref>]. On the other hand, an increase in Lp(a) may be associated with a decrease in the relative risk of developing diabetes mellitus [<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>].</p>
</sec>
</sec>
<sec id="sec3.3">
<title>3.3. Endotype, Associated with Arterial Injury (Arterial Hypertension)</title>
<sec id="sec3.3.1">
<title>3.3.1. Background</title>
<p>Hypertension is a proven “driver” of atherosclerosis with an established genetic substrate, which currently makes up more than 120 loci [<xref ref-type="bibr" rid="B61">61</xref>]. Hypertension, endothelial dysfunction, and vascular stiffness are closely interrelated and constitute an independent pathophysiological atherogenesis cluster.</p>
<p>Polymorphisms associated with elevated blood pressure also lead to the development of disorders in the normal physiology of the vessel: the migration of smooth muscle cells in response to damage (ADAMTS7), endothelial cell migration and neointimal repair, and remodeling of small resistance arteries [<xref ref-type="bibr" rid="B61">61</xref>].</p>
</sec>
<sec id="sec3.3.2">
<title>3.3.2. Genetics</title>
<p>Currently, numerous genetic loci that determine the normal physiology of the vessel have been discovered: ADAMTS7, THBS2, CFDP1, NOX4, EDNRA, PHACTR1, GUCY1A3, CNNM2, CYP17A1, etc. [<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>].</p>
<p>The significant role of proteins that play a role in maintaining vascular homeostasis in atherogenesis has been demonstrated in a number of studies using proteomics technologies, for example, FBLN1C (fibulins) [<xref ref-type="bibr" rid="B63">63</xref>].</p>
<p>Mutations in these genes cause, on the one hand, the development of hypertension, endothelial dysfunction, and an increase in vascular stiffness, and on the other hand, the development of atherosclerosis.</p>
</sec>
<sec id="sec3.3.3">
<title>3.3.3. Biomarkers</title>
<p>Biomarkers associated with arterial injury include the following: endothelin, angiotensin, adrenomedullin, natriuretic peptides, von Willebrand factor, cell adhesion molecules, endothelial progenitor cells, endothelial microparticles, nitric oxide, and asymmetric dimethylarginine.</p>
</sec>
<sec id="sec3.3.4">
<title>3.3.4. Clinical Features and Comorbid Conditions</title>
<p>The states that are, in particular causally, associated with hypertension include the following: hemorrhagic stroke, chronic kidney disease, atrial fibrillation, vascular dementia, and left ventricular hypertrophy [<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>].</p>
</sec>
</sec>
<sec id="sec3.4">
<title>3.4. Endotype, Associated Mainly with the Activity of Inflammation</title>
<sec id="sec3.4.1">
<title>3.4.1. Background</title>
<p>Inflammation, the driver of which is represented by various proatherogenic lipoproteins, is considered as the central mechanism of atherogenesis [<xref ref-type="bibr" rid="B66">66</xref>]. CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) confirmed the “inflammatory hypothesis” of atherothrombosis [<xref ref-type="bibr" rid="B67">67</xref>].</p>
<p>Atherogenesis in systemic inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.) proceeds at an accelerated rate regardless of the presence of classical risk factors and is determined mainly by the activity of systemic inflammation, as well as duration and phenotype of the disease [<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B69">69</xref>].</p>
</sec>
<sec id="sec3.4.2">
<title>3.4.2. Genetics</title>
<p>The following genes involved in the regulation of various pathways of inflammation, according to various GWAS, are significantly associated with atherosclerotic cardiovascular diseases (CVD): CXCL12, MCP-1, TLRs, SH2B3, HLA, IL-6R, IL-5, PECAM1, and others [<xref ref-type="bibr" rid="B70">70</xref>]. In studies based on the proteomics approach, the crucial role of inflammation was also shown by the example of the activation of the TNF-<italic>α</italic> pathway in the vascular wall, as well as the migration of monocytes into the subendothelial compartment (ANRIL) [<xref ref-type="bibr" rid="B71">71</xref>, <xref ref-type="bibr" rid="B72">72</xref>].</p>
<p>Metabolomics studies have demonstrated strong relationships between the level of metabolites reflecting the activity of the inflammatory response, such as N-acetylneuraminic acid and lactate, and the progression of atherosclerosis [<xref ref-type="bibr" rid="B73">73</xref>].</p>
<p>Moreover, mutations in key genes determining cellular interactions of immunocompetent cells cause, on the one hand, the development of atherosclerotic CVD, and on the other, systemic inflammatory diseases, such as rheumatoid arthritis [<xref ref-type="bibr" rid="B74">74</xref>]. These key genes include the HLA gene (HLA-DRB1∗04), TNF, and IL-1 [<xref ref-type="bibr" rid="B74">74</xref>].</p>
</sec>
<sec id="sec3.4.3">
<title>3.4.3. Biomarkers</title>
<p>Biomarkers associated mainly with the activity of inflammation include the following: TNF, IL-1b, IL-6, IL-12, IL-18, IL-23, IFN-g, IL-17, IL-22, TH17 cells, hsCRP, pentraxin-3, sCD40L, VCAM, and ICAM [<xref ref-type="bibr" rid="B75">75</xref>].</p>
</sec>
<sec id="sec3.4.4">
<title>3.4.4. Clinical Features and Comorbid Conditions</title>
<p>This endotype is most pronounced in chronic systemic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and ankylosing spondylitis. The severity and speed of atherosclerosis development in rheumatoid arthritis and systemic lupus erythematosus are similar to those in diabetes mellitus [<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>]. The relative risk of carotid plaque detection in patients with systemic lupus erythematosus is 2.4 times higher than in the general population, and the maximum risk (5.6 times) is observed in patients younger than 40 years old [<xref ref-type="bibr" rid="B78">78</xref>]. In patients with chronic inflammatory diseases, phenotypically unstable plaques are found more frequent with less stenosing of the lumen of the vessels [<xref ref-type="bibr" rid="B79">79</xref>].</p>
<p>Among the comorbid conditions associated with chronic inflammatory diseases, the high frequency of solid tumors (in the prostate, mammary glands, uterus, and skin), mental disorders (depression and psychosis), and osteoporosis should be noted [<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B81">81</xref>].</p>
</sec>
</sec>
<sec id="sec3.5">
<title>3.5. Endotype, Associated with Metabolic Risk Factors</title>
<sec id="sec3.5.1">
<title>3.5.1. Background</title>
<p>Diabetes mellitus and a cluster of metabolic risk factors (hyperglycemia and obesity) have been considered for many years as an independent predictor of atherosclerosis. Diabetes mellitus implements proatherogenic effects through a variety of mechanisms: hyperglycemia, insulin resistance, reduced nitric oxide bioavailability, oxidative stress, systemic inflammation, etc. [<xref ref-type="bibr" rid="B82">82</xref>].</p>
</sec>
<sec id="sec3.5.2">
<title>3.5.2. Genetics</title>
<p>According to GWAS, 24% of the loci associated with the development of diabetes also increase the risk of atherosclerosis [<xref ref-type="bibr" rid="B83">83</xref>]. Genetic variants associated with diabetes independently increase the risk of CAD, taking into account gene pleiotropy and general pathophysiological pathways (dyslipidemia, hypertension, etc.) [<xref ref-type="bibr" rid="B84">84</xref>]. In addition, studies using the metabolomics approach have demonstrated strong relationships between the levels of D-glucose, 1,5-anhydrosorbitol, D-mannose, and myoinositol, and the development of atherosclerosis [<xref ref-type="bibr" rid="B73">73</xref>].</p>
<p>Currently, seven variants are known that are common elements in the genetic architecture of diabetes and atherosclerosis: TCF7L2, HNF1A, CTRB1/2, MRAS, ZC3HC1, MIR17HG, and CCDC92 [<xref ref-type="bibr" rid="B84">84</xref>].</p>
</sec>
<sec id="sec3.5.3">
<title>3.5.3. Biomarkers</title>
<p>Biomarkers associated mainly with metabolic risk factors include the following: blood glucose, blood insulin, C-peptide, glycated hemoglobin, glycated albumin, sRAGE, fructosamine, etc. [<xref ref-type="bibr" rid="B85">85</xref>].</p>
</sec>
<sec id="sec3.5.4">
<title>3.5.4. Clinical Features and Comorbid Conditions</title>
<p>Diabetes contributes to the development of medial calcinosis. Medial calcinosis, in turn, significantly limits “positive” vessel remodeling in response to plaque growth, which probably leads to an increase in the frequency of occlusive diffuse polyvascular diseases in diabetes [<xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B86">86</xref>]. Moreover, in small caliber arteries (for example, the tibial arteries), the phase of “positive” remodeling may be absent, which leads to early development of occlusive lesion. Diabetes is probably a protective factor in the development of abdominal aortic aneurysm [<xref ref-type="bibr" rid="B87">87</xref>].</p>
<p>Among the comorbid conditions associated with a cluster of metabolic risk factors, the following are included: psoriasis, Alzheimer's disease, affective disorders, and cancer (colorectal, pancreas, breast, and kidney) [<xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B89">89</xref>].</p>
</sec>
</sec>
</sec>
<sec id="sec4">
<title>4. Сoncluding Remarks</title>
<p>We have a few comments on the proposed endotypes of atherosclerosis. First, we did not include in our proposed model an endotype associated with an increase in the level of homocysteine. The causal role of homocysteine in the development of atherosclerosis and CVD has not yet been proven and, in general, data on the role of homocysteine are contradictory. According to GWAS, which included 44,147 people, genetic variants that affect plasma homocysteine concentrations are not associated with the risk of CAD [<xref ref-type="bibr" rid="B90">90</xref>]. The results of large-scale studies with Mendelian randomization also do not confirm the causal role of homocysteine in the development of atherosclerotic CVDs [<xref ref-type="bibr" rid="B91">91</xref>].</p>
<p>Secondly, the value of HDL in the development of atherosclerosis has also not been established to date. The protective role of an increase in HDL and the proatherogenic effects of a decrease in HDL are subject to reasonable doubt [<xref ref-type="bibr" rid="B92">92</xref>]. Research data with Mendelian randomization also do not confirm the causal role of HDL in the development of atherosclerotic CVDs [<xref ref-type="bibr" rid="B93">93</xref>].</p>
<p>Thirdly, the hemostatic system plays an extremely important role in vascular biology and atherogenesis. However, according to currently available data, the role of the hemostasis system is realized mainly in the late stages of atherogenesis, determining the prognosis of patients who are already clinically manifesting atherosclerotic CVD [<xref ref-type="bibr" rid="B94">94</xref>]. In this regard, we also did not propose an endotype, associated mainly with disorders in the hemostasis system.</p>
</sec>
<sec id="sec5">
<title>5. Clinical Implications and Perspectives</title>
<p>In recent years, the concept of residual cardiovascular risks has been actively developed, designed to facilitate the study of the mechanisms of adverse cardiovascular events in patients with atherosclerotic CVD receiving optimal medical therapy [<xref ref-type="bibr" rid="B95">95</xref>]. To date, a number of researchers have identified lipid, inflammatory, thrombotic, and metabolic residual risks [<xref ref-type="bibr" rid="B96">96</xref>]. Residual risk associated with an increase in Lp(a) is also considered [<xref ref-type="bibr" rid="B97">97</xref>].</p>
<p>According to Patel et al., the current guideline-based approach is not patient-specific enough and does not allow influencing the causal mechanisms leading to the progression of atherosclerotic CVD [<xref ref-type="bibr" rid="B96">96</xref>]. The concept of residual risks in this case should contribute to the recognition in patients of different pathophysiological mechanisms, of which the contribution to the progression of CVD is a leading one, and the impact on which will bring maximum benefit to the patient.</p>
<p>Thus, conceptualization of the pathogenetic heterogeneity of atherosclerosis and atherosclerotic CVDs at the late stages of atherogenesis occurs. Paradoxically, understanding this heterogeneity at the stages of initiation and development of atherosclerosis develops rather slowly. However, specific interventions in the early stages of atherosclerosis can be much more effective and beneficial for both the patient and the health care system as a whole.</p>
<p>Studies using the omics approach are extremely promising in this context. Moreover, these studies today provide examples of early individualized diagnosis of chronic cardiometabolic diseases, which is a significant progress in precision medicine [<xref ref-type="bibr" rid="B98">98</xref>].</p>
<p>Further study of the genetics of cardiovascular diseases and the use of approaches based on system biology and machine learning will probably make it possible to make substantial progress in this area in the near future.</p>
</sec>
</body>
<back>
<sec sec-type="COI-statement">
<title>Conflicts of Interest</title>
<p>All authors declare no conflict of interest.</p>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottesman</surname>
<given-names>I. I.</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>T. D.</given-names>
</name>
</person-group>
<article-title>The endophenotype concept in psychiatry: etymology and strategic intentions</article-title>
<source/>
<italic toggle="yes">American Journal of Psychiatry</italic>
<year>2003</year>
<volume>160</volume>
<issue>4</issue>
<fpage>636</fpage>
<lpage>645</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.160.4.636</pub-id>
<pub-id pub-id-type="other">2-s2.0-0038823525</pub-id>
<pub-id pub-id-type="pmid">12668349</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gould</surname>
<given-names>T. D.</given-names>
</name>
<name>
<surname>Gottesman</surname>
<given-names>I. I.</given-names>
</name>
</person-group>
<article-title>Psychiatric endophenotypes and the development of valid animal models</article-title>
<source/>
<italic toggle="yes">Genes, Brain, and Behavior</italic>
<year>2006</year>
<volume>5</volume>
<issue>2</issue>
<fpage>113</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2005.00186.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-33644753148</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariutina</surname>
<given-names>T. M.</given-names>
</name>
</person-group>
<article-title>Endophenotypes in psychiatric genetics: experience of ten years long study (literature overview)</article-title>
<source/>
<italic toggle="yes">Journal of Modern Foreign Psychology</italic>
<year>2013</year>
<volume>2</volume>
<issue>4</issue>
<fpage>45</fpage>
<lpage>58</lpage>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Smoller</surname>
<given-names>J. W.</given-names>
</name>
</person-group>
<article-title>A new role for endophenotypes in the GWAS era: functional characterization of risk variants</article-title>
<source/>
<italic toggle="yes">Harvard Review of Psychiatry</italic>
<year>2010</year>
<volume>18</volume>
<issue>1</issue>
<fpage>67</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.3109/10673220903523532</pub-id>
<pub-id pub-id-type="other">2-s2.0-74949122483</pub-id>
<pub-id pub-id-type="pmid">20047462</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beauchaine</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Constantino</surname>
<given-names>J. N.</given-names>
</name>
</person-group>
<article-title>Redefining the endophenotype concept to accommodate transdiagnostic vulnerabilities and etiological complexity</article-title>
<source/>
<italic toggle="yes">Biomarkers in Medicine</italic>
<year>2017</year>
<volume>11</volume>
<issue>9</issue>
<fpage>769</fpage>
<lpage>780</lpage>
<pub-id pub-id-type="doi">10.2217/bmm-2017-0002</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029809927</pub-id>
<pub-id pub-id-type="pmid">28891303</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenzenweger</surname>
<given-names>M. F.</given-names>
</name>
</person-group>
<article-title>Thinking clearly about endophenotype–intermediate phenotype–biomarker distinctions in developmental psychopathology research</article-title>
<source/>
<italic toggle="yes">Development and Psychopathology</italic>
<year>2013</year>
<volume>25, 4, Part 2</volume>
<fpage>1347</fpage>
<lpage>1357</lpage>
<pub-id pub-id-type="doi">10.1017/S0954579413000655</pub-id>
<pub-id pub-id-type="other">2-s2.0-84891419475</pub-id>
<pub-id pub-id-type="pmid">24342844</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<collab>Biomarkers Definitions Working Group</collab>
<article-title>Biomarkers and surrogate endpoints: preferred definitions and conceptual framework</article-title>
<source/>
<italic toggle="yes">Clinical Pharmacology &amp; Therapeutics</italic>
<year>2001</year>
<volume>69</volume>
<issue>3</issue>
<fpage>89</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1067/mcp.2001.113989</pub-id>
<pub-id pub-id-type="other">2-s2.0-0035100888</pub-id>
<pub-id pub-id-type="pmid">11240971</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iacono</surname>
<given-names>W. G.</given-names>
</name>
</person-group>
<article-title>Endophenotypes in psychiatric disease: prospects and challenges</article-title>
<source/>
<italic toggle="yes">Genome Medicine</italic>
<year>2018</year>
<volume>10</volume>
<issue>1</issue>
<fpage>p. 11</fpage>
<pub-id pub-id-type="doi">10.1186/s13073-018-0526-5</pub-id>
<pub-id pub-id-type="other">2-s2.0-85042402931</pub-id>
<pub-id pub-id-type="pmid">29471866</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruparelia</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Manji</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Abubakar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>C. R.</given-names>
</name>
</person-group>
<article-title>Investigating the evidence of behavioral, cognitive, and psychiatric endophenotypes in autism: a systematic review</article-title>
<source/>
<italic toggle="yes">Autism Research and Treatment</italic>
<year>2017</year>
<volume>2017</volume>
<fpage>17</fpage>
<pub-id pub-id-type="publisher-id">6346912</pub-id>
<pub-id pub-id-type="doi">10.1155/2017/6346912</pub-id>
<pub-id pub-id-type="pmid">28761767</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braff</surname>
<given-names>D. L.</given-names>
</name>
</person-group>
<article-title>The importance of endophenotypes in schizophrenia research</article-title>
<source/>
<italic toggle="yes">Schizophrenia Research</italic>
<year>2015</year>
<volume>163</volume>
<issue>1-3</issue>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2015.02.007</pub-id>
<pub-id pub-id-type="other">2-s2.0-84925869807</pub-id>
<pub-id pub-id-type="pmid">25795083</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Identification of risk-conferring genes of schizophrenia using endophenotypes</article-title>
<source/>
<italic toggle="yes">Neuropsychiatry</italic>
<year>2017</year>
<volume>7</volume>
<issue>5</issue>
<fpage>717</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.4172/Neuropsychiatry.1000269</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shoda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Aceves</surname>
<given-names>S. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study</article-title>
<source/>
<italic toggle="yes">The Lancet Gastroenterology &amp; Hepatology</italic>
<year>2018</year>
<volume>3</volume>
<issue>7</issue>
<fpage>477</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="doi">10.1016/S2468-1253(18)30096-7</pub-id>
<pub-id pub-id-type="other">2-s2.0-85046753556</pub-id>
<pub-id pub-id-type="pmid">29730081</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manjarrez-Orduño</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Menard</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Carman</surname>
<given-names>J. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A systemic lupus erythematosus endophenotype characterized by increased CD8 cytotoxic signature associates with renal involvement</article-title>
<source/>
<italic toggle="yes">ImmunoHorizons</italic>
<year>2017</year>
<volume>1</volume>
<issue>7</issue>
<fpage>124</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="doi">10.4049/immunohorizons.1700028</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavord</surname>
<given-names>I. D.</given-names>
</name>
<name>
<surname>Beasley</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Agusti</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>After asthma: redefining airways diseases</article-title>
<source/>
<italic toggle="yes">The Lancet</italic>
<year>2018</year>
<volume>391</volume>
<issue>10118</issue>
<fpage>350</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(17)30879-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029208732</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>G. P.</given-names>
</name>
</person-group>
<article-title>Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease</article-title>
<source/>
<italic toggle="yes">The Lancet</italic>
<year>2008</year>
<volume>372</volume>
<issue>9643</issue>
<fpage>1107</fpage>
<lpage>1119</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(08)61452-X</pub-id>
<pub-id pub-id-type="other">2-s2.0-52049087356</pub-id>
<pub-id pub-id-type="pmid">18805339</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hargreave</surname>
<given-names>F. E.</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>The definition and diagnosis of asthma</article-title>
<source/>
<italic toggle="yes">Clinical &amp; Experimental Allergy</italic>
<year>2009</year>
<volume>39</volume>
<issue>11</issue>
<fpage>1652</fpage>
<lpage>1658</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2222.2009.03321.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-70350318929</pub-id>
<pub-id pub-id-type="pmid">19622089</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozdemir</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kucuksezer</surname>
<given-names>U. C.</given-names>
</name>
<name>
<surname>Akdis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akdis</surname>
<given-names>C. A.</given-names>
</name>
</person-group>
<article-title>The concepts of asthma endotypes and phenotypes to guide current and novel treatment strategies</article-title>
<source/>
<italic toggle="yes">Expert Review of Respiratory Medicine</italic>
<year>2018</year>
<volume>12</volume>
<issue>9</issue>
<fpage>733</fpage>
<lpage>743</lpage>
<pub-id pub-id-type="doi">10.1080/17476348.2018.1505507</pub-id>
<pub-id pub-id-type="other">2-s2.0-85052950009</pub-id>
<pub-id pub-id-type="pmid">30084271</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lötvall</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Akdis</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Bacharier</surname>
<given-names>L. B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome</article-title>
<source/>
<italic toggle="yes">Journal of Allergy and Clinical Immunology</italic>
<year>2011</year>
<volume>127</volume>
<issue>2</issue>
<fpage>355</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2010.11.037</pub-id>
<pub-id pub-id-type="other">2-s2.0-79551505136</pub-id>
<pub-id pub-id-type="pmid">21281866</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dean</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Niven</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Asthma phenotypes and endotypes: implications for personalised therapy</article-title>
<source/>
<italic toggle="yes">BioDrugs</italic>
<year>2017</year>
<volume>31</volume>
<issue>5</issue>
<fpage>393</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1007/s40259-017-0242-5</pub-id>
<pub-id pub-id-type="other">2-s2.0-85028820140</pub-id>
<pub-id pub-id-type="pmid">28879503</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russell</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Baillie</surname>
<given-names>J. K.</given-names>
</name>
</person-group>
<article-title>Treatable traits and therapeutic targets: goals for systems biology in infectious disease</article-title>
<source/>
<italic toggle="yes">Current Opinion in Systems Biology</italic>
<year>2017</year>
<volume>2</volume>
<fpage>140</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1016/j.coisb.2017.04.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-85044748769</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Jutel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gajdanowicz</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Revised disease nomenclature including disease endotypes</article-title>
<source/>
<italic toggle="yes">Implementing Precision Medicine in Best Practices of Chronic Airway Diseases</italic>
<year>2018</year>
<publisher-loc>London, UK</publisher-loc>
<publisher-name>Academic Press</publisher-name>
<fpage>27</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/b978-0-12-813471-9.00029-3</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Schelbert</surname>
<given-names>E. B.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>S. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biological phenotypes of heart failure with preserved ejection fraction</article-title>
<source/>
<italic toggle="yes">Journal of the American College of Cardiology</italic>
<year>2017</year>
<volume>70</volume>
<issue>17</issue>
<fpage>2186</fpage>
<lpage>2200</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2017.09.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-85032144648</pub-id>
<pub-id pub-id-type="pmid">29050567</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Selvaraj</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenomapping for novel classification of heart failure with preserved ejection fraction</article-title>
<source/>
<italic toggle="yes">Circulation</italic>
<year>2015</year>
<volume>131</volume>
<issue>3</issue>
<fpage>269</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.010637</pub-id>
<pub-id pub-id-type="other">2-s2.0-84927626763</pub-id>
<pub-id pub-id-type="pmid">25398313</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tromp</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ouwerkerk</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Demissei</surname>
<given-names>B. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel endotypes in heart failure: effects on guideline-directed medical therapy</article-title>
<source/>
<italic toggle="yes">European Heart Journal</italic>
<year>2018</year>
<volume>39</volume>
<issue>48</issue>
<fpage>4269</fpage>
<lpage>4276</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehy712</pub-id>
<pub-id pub-id-type="other">2-s2.0-85058909982</pub-id>
<pub-id pub-id-type="pmid">30551207</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ponikowski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Voors</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Anker</surname>
<given-names>S. D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</article-title>
<source/>
<italic toggle="yes">European Journal of Heart Failure</italic>
<year>2016</year>
<volume>18</volume>
<issue>8</issue>
<fpage>891</fpage>
<lpage>975</lpage>
<pub-id pub-id-type="doi">10.1002/ejhf.592</pub-id>
<pub-id pub-id-type="other">2-s2.0-84981715657</pub-id>
<pub-id pub-id-type="pmid">27207191</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrating hypertension phenotype and genotype with hybrid non-negative matrix factorization</article-title>
<source/>
<italic toggle="yes">Bioinformatics</italic>
<year>2019</year>
<volume>35</volume>
<issue>8</issue>
<fpage>1395</fpage>
<lpage>1403</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/bty804</pub-id>
<pub-id pub-id-type="other">2-s2.0-85068538210</pub-id>
<pub-id pub-id-type="pmid">30239588</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baudrand</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vaidya</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor</article-title>
<source/>
<italic toggle="yes">International Journal of Molecular Sciences</italic>
<year>2018</year>
<volume>19</volume>
<issue>2</issue>
<fpage>p. 546</fpage>
<pub-id pub-id-type="doi">10.3390/ijms19020546</pub-id>
<pub-id pub-id-type="other">2-s2.0-85042061134</pub-id>
<pub-id pub-id-type="pmid">29439489</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korner</surname>
<given-names>P. I.</given-names>
</name>
</person-group>
<article-title>The phenotypic patterns of essential hypertension are the key to identifying “high blood pressure” genes</article-title>
<source/>
<italic toggle="yes">Physiological Research</italic>
<year>2010</year>
<volume>59</volume>
<issue>6</issue>
<fpage>841</fpage>
<lpage>857</lpage>
<pub-id pub-id-type="pmid">21208016</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dudenbostel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gharpure</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Calhoun</surname>
<given-names>D. A.</given-names>
</name>
</person-group>
<article-title>Refractory versus resistant hypertension: novel distinctive phenotypes</article-title>
<source/>
<italic toggle="yes">Journal of Nature and Science</italic>
<year>2017</year>
<volume>3</volume>
<issue>9, article e430</issue>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramsey</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Aderem</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A systems biology approach to understanding atherosclerosis</article-title>
<source/>
<italic toggle="yes">EMBO Molecular Medicine</italic>
<year>2010</year>
<volume>2</volume>
<issue>3</issue>
<fpage>79</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1002/emmm.201000063</pub-id>
<pub-id pub-id-type="other">2-s2.0-77953681096</pub-id>
<pub-id pub-id-type="pmid">20201031</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farrer</surname>
<given-names>L. A.</given-names>
</name>
</person-group>
<article-title>Collection of clinical and epidemiological data for linkage studies</article-title>
<source/>
<italic toggle="yes">Current Protocols in Human Genetics</italic>
<year>2004</year>
<volume>40</volume>
<issue>1</issue>
<fpage>1.1.1</fpage>
<lpage>1.1.17</lpage>
<pub-id pub-id-type="doi">10.1002/0471142905.hg0101s40</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Wyszynski</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>L. A.</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Loscalzo</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Genetics of atherosclerosis in humans</article-title>
<source/>
<italic toggle="yes">Molecular Mechanisms of Atherosclerosis</italic>
<year>2005</year>
<publisher-name>Taylor &amp; Francis</publisher-name>
<fpage>37</fpage>
<lpage>59</lpage>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lusis</surname>
<given-names>A. J.</given-names>
</name>
</person-group>
<article-title>Atherosclerosis</article-title>
<source/>
<italic toggle="yes">Nature</italic>
<year>2000</year>
<volume>407</volume>
<issue>6801</issue>
<fpage>233</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1038/35025203</pub-id>
<pub-id pub-id-type="other">2-s2.0-0034648768</pub-id>
<pub-id pub-id-type="pmid">11001066</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Scheidt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kurt</surname>
<given-names>Z.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Applications and limitations of mouse models for understanding human atherosclerosis</article-title>
<source/>
<italic toggle="yes">Cell Metabolism</italic>
<year>2017</year>
<volume>25</volume>
<issue>2</issue>
<fpage>248</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2016.11.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-85007449433</pub-id>
<pub-id pub-id-type="pmid">27916529</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Systematic analysis of the molecular mechanism underlying atherosclerosis using a text mining approach</article-title>
<source/>
<italic toggle="yes">Human Genomics</italic>
<year>2016</year>
<volume>10</volume>
<issue>1</issue>
<fpage>p. 14</fpage>
<pub-id pub-id-type="doi">10.1186/s40246-016-0075-1</pub-id>
<pub-id pub-id-type="other">2-s2.0-85026880579</pub-id>
<pub-id pub-id-type="pmid">27251057</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webb</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Erdmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stirrups</surname>
<given-names>K. E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systematic evaluation of pleiotropy identifies 6 further loci associated with coronary artery disease</article-title>
<source/>
<italic toggle="yes">Journal of the American College of Cardiology</italic>
<year>2017</year>
<volume>69</volume>
<issue>7</issue>
<fpage>823</fpage>
<lpage>836</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2016.11.056</pub-id>
<pub-id pub-id-type="other">2-s2.0-85013005062</pub-id>
<pub-id pub-id-type="pmid">28209224</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holdt</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Teupser</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>From genotype to phenotype in human atherosclerosis - recent findings</article-title>
<source/>
<italic toggle="yes">Current Opinion in Lipidology</italic>
<year>2013</year>
<volume>24</volume>
<issue>5</issue>
<fpage>410</fpage>
<lpage>418</lpage>
<pub-id pub-id-type="doi">10.1097/MOL.0b013e3283654e7c</pub-id>
<pub-id pub-id-type="other">2-s2.0-84883780487</pub-id>
<pub-id pub-id-type="pmid">24005217</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Application of causal inference to genomic analysis: advances in methodology</article-title>
<source/>
<italic toggle="yes">Frontiers in Genetics</italic>
<year>2018</year>
<volume>9</volume>
<fpage>p. 238</fpage>
<pub-id pub-id-type="doi">10.3389/fgene.2018.00238</pub-id>
<pub-id pub-id-type="other">2-s2.0-85049642286</pub-id>
<pub-id pub-id-type="pmid">30042787</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frayling</surname>
<given-names>T. M.</given-names>
</name>
</person-group>
<article-title>Genome-wide association studies: the good, the bad and the ugly</article-title>
<source/>
<italic toggle="yes">Clinical Medicine</italic>
<year>2014</year>
<volume>14</volume>
<issue>4</issue>
<fpage>428</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.7861/clinmedicine.14-4-428</pub-id>
<pub-id pub-id-type="other">2-s2.0-84906084658</pub-id>
<pub-id pub-id-type="pmid">25099848</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leon-Mimila</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huertas-Vazquez</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Relevance of multi-omics studies in cardiovascular diseases</article-title>
<source/>
<italic toggle="yes">Frontiers in Cardiovascular Medicine</italic>
<year>2019</year>
<volume>6</volume>
<fpage>p. 91</fpage>
<pub-id pub-id-type="doi">10.3389/fcvm.2019.00091</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ference</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Ginsberg</surname>
<given-names>H. N.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel</article-title>
<source/>
<italic toggle="yes">European Heart Journal</italic>
<year>2017</year>
<volume>38</volume>
<issue>32</issue>
<fpage>2459</fpage>
<lpage>2472</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehx144</pub-id>
<pub-id pub-id-type="other">2-s2.0-85027715986</pub-id>
<pub-id pub-id-type="pmid">28444290</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lusis</surname>
<given-names>A. J.</given-names>
</name>
</person-group>
<article-title>Genetics of atherosclerosis</article-title>
<source/>
<italic toggle="yes">Trends in Genetics</italic>
<year>2012</year>
<volume>28</volume>
<issue>6</issue>
<fpage>267</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="doi">10.1016/j.tig.2012.03.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-84861530209</pub-id>
<pub-id pub-id-type="pmid">22480919</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shalhoub</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sikkel</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Vorkas</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Want</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>A. H.</given-names>
</name>
</person-group>
<article-title>Systems biology of human atherosclerosis</article-title>
<source/>
<italic toggle="yes">Vascular and Endovascular Surgery</italic>
<year>2014</year>
<volume>48</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1177/1538574413510628</pub-id>
<pub-id pub-id-type="other">2-s2.0-84890926667</pub-id>
<pub-id pub-id-type="pmid">24212404</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okuyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hamazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hama</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A critical review of the consensus statement from the European Atherosclerosis Society Consensus Panel 2017</article-title>
<source/>
<italic toggle="yes">Pharmacology</italic>
<year>2018</year>
<volume>101</volume>
<issue>3-4</issue>
<fpage>184</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="doi">10.1159/000486374</pub-id>
<pub-id pub-id-type="other">2-s2.0-85040993019</pub-id>
<pub-id pub-id-type="pmid">29353277</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Musunuru</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Frank-Kamenetsky</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>From noncoding variant to phenotype via <italic>SORT</italic>1 at the 1p13 cholesterol locus</article-title>
<source/>
<italic toggle="yes">Nature</italic>
<year>2010</year>
<volume>466</volume>
<issue>7307</issue>
<fpage>714</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="doi">10.1038/nature09266</pub-id>
<pub-id pub-id-type="other">2-s2.0-77955499945</pub-id>
<pub-id pub-id-type="pmid">20686566</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K. H. K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Shared genetic regulatory networks for cardiovascular disease and type 2 diabetes in multiple populations of diverse ethnicities in the United States</article-title>
<source/>
<italic toggle="yes">PLoS Genetics</italic>
<year>2017</year>
<volume>13</volume>
<issue>9, article e1007040</issue>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1007040</pub-id>
<pub-id pub-id-type="other">2-s2.0-85031321028</pub-id>
<pub-id pub-id-type="pmid">28957322</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reitz</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Dyslipidemia and the risk of Alzheimer’s disease</article-title>
<source/>
<italic toggle="yes">Current Atherosclerosis Reports</italic>
<year>2013</year>
<volume>15</volume>
<issue>3</issue>
<fpage>p. 307</fpage>
<pub-id pub-id-type="doi">10.1007/s11883-012-0307-3</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872186742</pub-id>
<pub-id pub-id-type="pmid">23328907</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Gim</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Yeo</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H. S.</given-names>
</name>
</person-group>
<article-title>Integrated late onset Alzheimer’s disease (LOAD) susceptibility genes: cholesterol metabolism and trafficking perspectives</article-title>
<source/>
<italic toggle="yes">Gene</italic>
<year>2017</year>
<volume>597</volume>
<fpage>10</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2016.10.022</pub-id>
<pub-id pub-id-type="other">2-s2.0-85001070143</pub-id>
<pub-id pub-id-type="pmid">27773727</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nowak</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ärnlöv</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A Mendelian randomization study of the effects of blood lipids on breast cancer risk</article-title>
<source/>
<italic toggle="yes">Nature Communications</italic>
<year>2018</year>
<volume>9</volume>
<issue>1</issue>
<fpage>p. 3957</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-018-06467-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-85054088248</pub-id>
<pub-id pub-id-type="pmid">30262900</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murtola</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Kasurinen</surname>
<given-names>T. V. J.</given-names>
</name>
<name>
<surname>Talala</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Taari</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tammela</surname>
<given-names>T. L. J.</given-names>
</name>
<name>
<surname>Auvinen</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer</article-title>
<source/>
<italic toggle="yes">Prostate Cancer and Prostatic Diseases</italic>
<year>2019</year>
<volume>22</volume>
<issue>1</issue>
<fpage>66</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1038/s41391-018-0087-0</pub-id>
<pub-id pub-id-type="other">2-s2.0-85053668371</pub-id>
<pub-id pub-id-type="pmid">30214034</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitahara</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Berrington de González</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>N. D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Total cholesterol and cancer risk in a large prospective study in Korea</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Oncology</italic>
<year>2011</year>
<volume>29</volume>
<issue>12</issue>
<fpage>1592</fpage>
<lpage>1598</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2010.31.5200</pub-id>
<pub-id pub-id-type="other">2-s2.0-79955040537</pub-id>
<pub-id pub-id-type="pmid">21422422</pub-id>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pirro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bianconi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Paciullo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mannarino</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Bagaglia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sahebkar</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Lipoprotein(a) and inflammation: a dangerous duet leading to endothelial loss of integrity</article-title>
<source/>
<italic toggle="yes">Pharmacological Research</italic>
<year>2017</year>
<volume>119</volume>
<fpage>178</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2017.02.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-85012057872</pub-id>
<pub-id pub-id-type="pmid">28185944</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsimikas</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The re-emergence of lipoprotein(a) in a broader clinical arena</article-title>
<source/>
<italic toggle="yes">Progress in Cardiovascular Diseases</italic>
<year>2016</year>
<volume>59</volume>
<issue>2</issue>
<fpage>135</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1016/j.pcad.2016.07.005</pub-id>
<pub-id pub-id-type="other">2-s2.0-84994274835</pub-id>
<pub-id pub-id-type="pmid">27497506</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Zychlinski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kleffmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>M. J. A.</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>S. P.</given-names>
</name>
</person-group>
<article-title>Proteomics of lipoprotein(a) identifies a protein complement associated with response to wounding</article-title>
<source/>
<italic toggle="yes">Journal of Proteomics</italic>
<year>2011</year>
<volume>74</volume>
<issue>12</issue>
<fpage>2881</fpage>
<lpage>2891</lpage>
<pub-id pub-id-type="doi">10.1016/j.jprot.2011.07.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-81055156223</pub-id>
<pub-id pub-id-type="pmid">21802535</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tmoyan</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Afanasieva</surname>
<given-names>O. I.</given-names>
</name>
<name>
<surname>Klesareva</surname>
<given-names>E. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The association of lipoprotein(a), apolipoprotein(a) phenotypes and autoantibodies to lipoprotein(a) with lower extremity artery disease</article-title>
<source/>
<italic toggle="yes">Kardiologiia</italic>
<year>2018</year>
<volume>58</volume>
<issue>12</issue>
<fpage>45</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.18087/cardio.2018.12.10176</pub-id>
<pub-id pub-id-type="other">2-s2.0-85059797449</pub-id>
<pub-id pub-id-type="pmid">30625096</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arsenault</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Boekholdt</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Dubé</surname>
<given-names>M. P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort</article-title>
<source/>
<italic toggle="yes">Circulation: Cardiovascular Genetics</italic>
<year>2014</year>
<volume>7</volume>
<issue>3</issue>
<fpage>304</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCGENETICS.113.000400</pub-id>
<pub-id pub-id-type="other">2-s2.0-84903123480</pub-id>
<pub-id pub-id-type="pmid">24704946</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capoulade</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yeang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Pibarot</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tsimikas</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial</article-title>
<source/>
<italic toggle="yes">JAMA Cardiology</italic>
<year>2018</year>
<volume>3</volume>
<issue>12</issue>
<fpage>1212</fpage>
<lpage>1217</lpage>
<pub-id pub-id-type="doi">10.1001/jamacardio.2018.3798</pub-id>
<pub-id pub-id-type="other">2-s2.0-85057097254</pub-id>
<pub-id pub-id-type="pmid">30476957</pub-id>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dentali</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gessi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Marcucci</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gianni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grandi</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Franchini</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Lipoprotein(a) as a risk factor for venous thromboembolism: a systematic review and meta-analysis of the literature</article-title>
<source/>
<italic toggle="yes">Seminars in Thrombosis and Hemostasis</italic>
<year>2017</year>
<volume>43</volume>
<issue>6</issue>
<fpage>614</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="doi">10.1055/s-0036-1598002</pub-id>
<pub-id pub-id-type="other">2-s2.0-85016590357</pub-id>
<pub-id pub-id-type="pmid">28346964</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paige</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Masconi</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Tsimikas</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature</article-title>
<source/>
<italic toggle="yes">Cardiovascular Diabetology</italic>
<year>2017</year>
<volume>16</volume>
<issue>1</issue>
<fpage>p. 38</fpage>
<pub-id pub-id-type="doi">10.1186/s12933-017-0520-z</pub-id>
<pub-id pub-id-type="other">2-s2.0-85015615301</pub-id>
<pub-id pub-id-type="pmid">28320383</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsimikas</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes</article-title>
<source/>
<italic toggle="yes">Journal of Lipid Research</italic>
<year>2018</year>
<volume>59</volume>
<issue>5</issue>
<fpage>741</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="doi">10.1194/jlr.C085639</pub-id>
<pub-id pub-id-type="other">2-s2.0-85046689012</pub-id>
<pub-id pub-id-type="pmid">29610122</pub-id>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>Evangelou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cabrera</surname>
<given-names>C. P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk</article-title>
<source/>
<italic toggle="yes">Nature Genetics</italic>
<year>2017</year>
<volume>49</volume>
<issue>3</issue>
<fpage>403</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3768</pub-id>
<pub-id pub-id-type="other">2-s2.0-85010952930</pub-id>
<pub-id pub-id-type="pmid">28135244</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verweij</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Eppinga</surname>
<given-names>R. N.</given-names>
</name>
<name>
<surname>Hagemeijer</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>van der Harst</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Identification of 15 novel risk loci for coronary artery disease and genetic risk of recurrent events, atrial fibrillation and heart failure</article-title>
<source/>
<italic toggle="yes">Scientific Reports</italic>
<year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>p. 2761</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-03062-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-85020437769</pub-id>
<pub-id pub-id-type="pmid">28584231</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhosale</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Moulder</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Venäläinen</surname>
<given-names>M. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum proteomic profiling to identify biomarkers of premature carotid atherosclerosis</article-title>
<source/>
<italic toggle="yes">Scientific Reports</italic>
<year>2018</year>
<volume>8</volume>
<issue>1</issue>
<fpage>p. 9209</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-27265-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-85048705188</pub-id>
<pub-id pub-id-type="pmid">29907817</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mancia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Spiering</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)</article-title>
<source/>
<italic toggle="yes">European Heart Journal</italic>
<year>2018</year>
<volume>39</volume>
<issue>33</issue>
<fpage>3021</fpage>
<lpage>3104</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehy339</pub-id>
<pub-id pub-id-type="other">2-s2.0-85051228836</pub-id>
<pub-id pub-id-type="pmid">30165516</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottesman</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Drill</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lotay</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bottinger</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Can genetic pleiotropy replicate common clinical constellations of cardiovascular disease and risk?</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2012</year>
<volume>7</volume>
<issue>9, article e46419</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0046419</pub-id>
<pub-id pub-id-type="other">2-s2.0-84867020651</pub-id>
<pub-id pub-id-type="pmid">23029515</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swirski</surname>
<given-names>F. K.</given-names>
</name>
<name>
<surname>Nahrendorf</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure</article-title>
<source/>
<italic toggle="yes">Science</italic>
<year>2013</year>
<volume>339</volume>
<issue>6116</issue>
<fpage>161</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1126/science.1230719</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872166189</pub-id>
<pub-id pub-id-type="pmid">23307733</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibañez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fuster</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>CANTOS: a gigantic proof-of-concept trial</article-title>
<source/>
<italic toggle="yes">Circulation Research</italic>
<year>2017</year>
<volume>121</volume>
<issue>12</issue>
<fpage>1320</fpage>
<lpage>1322</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.312200</pub-id>
<pub-id pub-id-type="other">2-s2.0-85037118294</pub-id>
<pub-id pub-id-type="pmid">29217712</pub-id>
</element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arida</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Protogerou</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Kitas</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Sfikakis</surname>
<given-names>P. P.</given-names>
</name>
</person-group>
<article-title>Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases</article-title>
<source/>
<italic toggle="yes">International Journal of Molecular Sciences</italic>
<year>2018</year>
<volume>19</volume>
<issue>7</issue>
<fpage>p. 1890</fpage>
<pub-id pub-id-type="doi">10.3390/ijms19071890</pub-id>
<pub-id pub-id-type="other">2-s2.0-85049202716</pub-id>
<pub-id pub-id-type="pmid">29954107</pub-id>
</element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skeoch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bruce</surname>
<given-names>I. N.</given-names>
</name>
</person-group>
<article-title>Atherosclerosis in rheumatoid arthritis: is it all about inflammation?</article-title>
<source/>
<italic toggle="yes">Nature Reviews Rheumatology</italic>
<year>2015</year>
<volume>11</volume>
<issue>7</issue>
<fpage>390</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1038/nrrheum.2015.40</pub-id>
<pub-id pub-id-type="other">2-s2.0-84933678127</pub-id>
<pub-id pub-id-type="pmid">25825281</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fava</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Montagnana</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Atherosclerosis is an inflammatory disease which lacks a common anti-inflammatory therapy: how human genetics can help to this issue. A narrative review</article-title>
<source/>
<italic toggle="yes">Frontiers in Pharmacology</italic>
<year>2018</year>
<volume>9</volume>
<fpage>p. 55</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2018.00055</pub-id>
<pub-id pub-id-type="other">2-s2.0-85041855314</pub-id>
<pub-id pub-id-type="pmid">29467655</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrington</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>S. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteomic architecture of human coronary and aortic atherosclerosis</article-title>
<source/>
<italic toggle="yes">Circulation</italic>
<year>2018</year>
<volume>137</volume>
<issue>25</issue>
<fpage>2741</fpage>
<lpage>2756</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.034365</pub-id>
<pub-id pub-id-type="other">2-s2.0-85058966247</pub-id>
<pub-id pub-id-type="pmid">29915101</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>G. Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long noncoding RNA <italic>ANRIL</italic> regulates endothelial cell activities associated with coronary artery disease by up-regulating <italic>CLIP1</italic>, <italic>EZR</italic>, and <italic>LYVE1</italic> genes</article-title>
<source/>
<italic toggle="yes">Journal of Biological Chemistry</italic>
<year>2019</year>
<volume>294</volume>
<issue>11</issue>
<fpage>3881</fpage>
<lpage>3898</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.RA118.005050</pub-id>
<pub-id pub-id-type="other">2-s2.0-85062949346</pub-id>
<pub-id pub-id-type="pmid">30655286</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tzoulaki</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Castagné</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Boulangé</surname>
<given-names>C. L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease</article-title>
<source/>
<italic toggle="yes">European Heart Journal</italic>
<year>2019</year>
<volume>40</volume>
<issue>34</issue>
<fpage>2883</fpage>
<lpage>2896</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehz235</pub-id>
<pub-id pub-id-type="other">2-s2.0-85067314112</pub-id>
<pub-id pub-id-type="pmid">31102408</pub-id>
</element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carbone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bonaventura</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liberale</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Atherosclerosis in rheumatoid arthritis: promoters and opponents</article-title>
<source/>
<italic toggle="yes">Clinical Reviews in Allergy &amp; Immunology</italic>
<year>2020</year>
<volume>58</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1007/s12016-018-8714-z</pub-id>
<pub-id pub-id-type="other">2-s2.0-85053936030</pub-id>
<pub-id pub-id-type="pmid">30259381</pub-id>
</element-citation>
</ref>
<ref id="B75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Netea</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Balkwill</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chonchol</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A guiding map for inflammation</article-title>
<source/>
<italic toggle="yes">Nature Immunology</italic>
<year>2017</year>
<volume>18</volume>
<issue>8</issue>
<fpage>826</fpage>
<lpage>831</lpage>
<pub-id pub-id-type="doi">10.1038/ni.3790</pub-id>
<pub-id pub-id-type="other">2-s2.0-85025833437</pub-id>
<pub-id pub-id-type="pmid">28722720</pub-id>
</element-citation>
</ref>
<ref id="B76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Protogerou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zampeli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tentolouris</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Makrilakis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kitas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sfikakis</surname>
<given-names>P. P.</given-names>
</name>
</person-group>
<article-title>Subclinical femoral atheromatosis in rheumatoid arthritis: comparable prevalence to diabetes mellitus in a case-control study</article-title>
<source/>
<italic toggle="yes">Annals of the Rheumatic Diseases</italic>
<year>2012</year>
<volume>71</volume>
<issue>9</issue>
<fpage>1534</fpage>
<lpage>1536</lpage>
<pub-id pub-id-type="doi">10.1136/annrheumdis-2011-201278</pub-id>
<pub-id pub-id-type="other">2-s2.0-84864866219</pub-id>
<pub-id pub-id-type="pmid">22764043</pub-id>
</element-citation>
</ref>
<ref id="B77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tektonidou</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Kravvariti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Konstantonis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tentolouris</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sfikakis</surname>
<given-names>P. P.</given-names>
</name>
<name>
<surname>Protogerou</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis</article-title>
<source/>
<italic toggle="yes">Autoimmunity Reviews</italic>
<year>2017</year>
<volume>16</volume>
<issue>3</issue>
<fpage>308</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/j.autrev.2017.01.009</pub-id>
<pub-id pub-id-type="other">2-s2.0-85012024997</pub-id>
<pub-id pub-id-type="pmid">28147263</pub-id>
</element-citation>
</ref>
<ref id="B78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teixeira</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>L. S.</given-names>
</name>
</person-group>
<article-title>Novel insights in systemic lupus erythematosus and atherosclerosis</article-title>
<source/>
<italic toggle="yes">Frontiers in Medicine</italic>
<year>2018</year>
<volume>4</volume>
<fpage>p. 262</fpage>
<pub-id pub-id-type="doi">10.3389/fmed.2017.00262</pub-id>
<pub-id pub-id-type="other">2-s2.0-85046944614</pub-id>
</element-citation>
</ref>
<ref id="B79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skeoch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cristinacce</surname>
<given-names>P. L. H.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation</article-title>
<source/>
<italic toggle="yes">Scientific Reports</italic>
<year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>p. 827</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-00989-w</pub-id>
<pub-id pub-id-type="other">2-s2.0-85018793612</pub-id>
<pub-id pub-id-type="pmid">28400572</pub-id>
</element-citation>
</ref>
<ref id="B80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>H. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence of co-morbidities and evaluation of their monitoring in Korean patients with rheumatoid arthritis: comparison with the results of an international, cross-sectional study (COMORA)</article-title>
<source/>
<italic toggle="yes">International Journal of Rheumatic Diseases</italic>
<year>2018</year>
<volume>21</volume>
<issue>7</issue>
<fpage>1414</fpage>
<lpage>1422</lpage>
<pub-id pub-id-type="doi">10.1111/1756-185X.13013</pub-id>
<pub-id pub-id-type="other">2-s2.0-85014312328</pub-id>
<pub-id pub-id-type="pmid">28261976</pub-id>
</element-citation>
</ref>
<ref id="B81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set</article-title>
<source/>
<italic toggle="yes">Clinical Rheumatology</italic>
<year>2018</year>
<volume>37</volume>
<issue>7</issue>
<fpage>1869</fpage>
<lpage>1878</lpage>
<pub-id pub-id-type="doi">10.1007/s10067-018-4086-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-85045148188</pub-id>
<pub-id pub-id-type="pmid">29637483</pub-id>
</element-citation>
</ref>
<ref id="B82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasterkamp</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Methods of accelerated atherosclerosis in diabetic patients</article-title>
<source/>
<italic toggle="yes">Heart</italic>
<year>2013</year>
<volume>99</volume>
<issue>10</issue>
<fpage>743</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="doi">10.1136/heartjnl-2011-301172</pub-id>
<pub-id pub-id-type="other">2-s2.0-84876545419</pub-id>
<pub-id pub-id-type="pmid">23598916</pub-id>
</element-citation>
</ref>
<ref id="B83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rasheed</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tikkanen</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease</article-title>
<source/>
<italic toggle="yes">Nature Genetics</italic>
<year>2017</year>
<volume>49</volume>
<issue>10</issue>
<fpage>1450</fpage>
<lpage>1457</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3943</pub-id>
<pub-id pub-id-type="other">2-s2.0-85030173238</pub-id>
<pub-id pub-id-type="pmid">28869590</pub-id>
</element-citation>
</ref>
<ref id="B84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gerstein</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Paré</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The genetic link between diabetes and atherosclerosis</article-title>
<source/>
<italic toggle="yes">Canadian Journal of Cardiology</italic>
<year>2018</year>
<volume>34</volume>
<issue>5</issue>
<fpage>565</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="doi">10.1016/j.cjca.2018.01.016</pub-id>
<pub-id pub-id-type="other">2-s2.0-85046102542</pub-id>
<pub-id pub-id-type="pmid">29731020</pub-id>
</element-citation>
</ref>
<ref id="B85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dorcely</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jagannathan</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel biomarkers for prediabetes, diabetes, and associated complications</article-title>
<source/>
<italic toggle="yes">Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</italic>
<year>2017</year>
<volume>10</volume>
<fpage>345</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="doi">10.2147/DMSO.S100074</pub-id>
<pub-id pub-id-type="other">2-s2.0-85032856609</pub-id>
<pub-id pub-id-type="pmid">28860833</pub-id>
</element-citation>
</ref>
<ref id="B86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fok</surname>
<given-names>P. W.</given-names>
</name>
<name>
<surname>Lanzer</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Media sclerosis drives and localizes atherosclerosis in peripheral arteries</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2018</year>
<volume>13</volume>
<issue>10, article e0205599</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0205599</pub-id>
<pub-id pub-id-type="other">2-s2.0-85055617536</pub-id>
<pub-id pub-id-type="pmid">30365531</pub-id>
</element-citation>
</ref>
<ref id="B87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raffort</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lareyre</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Clément</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hassen-Khodja</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chinetti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mallat</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Diabetes and aortic aneurysm: current state of the art</article-title>
<source/>
<italic toggle="yes">Cardiovascular Research</italic>
<year>2018</year>
<volume>114</volume>
<issue>13</issue>
<fpage>1702</fpage>
<lpage>1713</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvy174</pub-id>
<pub-id pub-id-type="other">2-s2.0-85055153942</pub-id>
<pub-id pub-id-type="pmid">30052821</pub-id>
</element-citation>
</ref>
<ref id="B88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Quaranta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prescott</surname>
<given-names>N. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease</article-title>
<source/>
<italic toggle="yes">Journal of Medical Genetics</italic>
<year>2008</year>
<volume>45</volume>
<issue>2</issue>
<fpage>114</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.053595</pub-id>
<pub-id pub-id-type="other">2-s2.0-39149111552</pub-id>
<pub-id pub-id-type="pmid">17993580</pub-id>
</element-citation>
</ref>
<ref id="B89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hruby</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>F. B.</given-names>
</name>
</person-group>
<article-title>The epidemiology of obesity: a big picture</article-title>
<source/>
<italic toggle="yes">PharmacoEconomics</italic>
<year>2015</year>
<volume>33</volume>
<issue>7</issue>
<fpage>673</fpage>
<lpage>689</lpage>
<pub-id pub-id-type="doi">10.1007/s40273-014-0243-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84933678058</pub-id>
<pub-id pub-id-type="pmid">25471927</pub-id>
</element-citation>
</ref>
<ref id="B90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Meurs</surname>
<given-names>J. B. J.</given-names>
</name>
<name>
<surname>Pare</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>S. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease</article-title>
<source/>
<italic toggle="yes">The American Journal of Clinical Nutrition</italic>
<year>2013</year>
<volume>98</volume>
<issue>3</issue>
<fpage>668</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="doi">10.3945/ajcn.112.044545</pub-id>
<pub-id pub-id-type="other">2-s2.0-84883163053</pub-id>
<pub-id pub-id-type="pmid">23824729</pub-id>
</element-citation>
</ref>
<ref id="B91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Parish</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Homocysteine and coronary heart disease: meta-analysis of <italic>MTHFR</italic> case-control studies, avoiding publication bias</article-title>
<source/>
<italic toggle="yes">PLoS Medicine</italic>
<year>2012</year>
<volume>9</volume>
<issue>2, article e1001177</issue>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1001177</pub-id>
<pub-id pub-id-type="other">2-s2.0-84857711683</pub-id>
<pub-id pub-id-type="pmid">22363213</pub-id>
</element-citation>
</ref>
<ref id="B92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubio-Perez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guney</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Aguilar</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic and functional characterization of disease associations explains comorbidity</article-title>
<source/>
<italic toggle="yes">Scientific Reports</italic>
<year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>p. 6207</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-04939-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-85026419425</pub-id>
</element-citation>
</ref>
<ref id="B93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Asselbergs</surname>
<given-names>F. W.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>T. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mendelian randomization of blood lipids for coronary heart disease</article-title>
<source/>
<italic toggle="yes">European Heart Journal</italic>
<year>2015</year>
<volume>36</volume>
<issue>9</issue>
<fpage>539</fpage>
<lpage>550</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/eht571</pub-id>
<pub-id pub-id-type="other">2-s2.0-84924420487</pub-id>
<pub-id pub-id-type="pmid">24474739</pub-id>
</element-citation>
</ref>
<ref id="B94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olie</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>van der Meijden</surname>
<given-names>P. E. J.</given-names>
</name>
<name>
<surname>Ten Cate</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The coagulation system in atherothrombosis: implications for new therapeutic strategies</article-title>
<source/>
<italic toggle="yes">Research and Practice in Thrombosis and Haemostasis</italic>
<year>2018</year>
<volume>2</volume>
<issue>2</issue>
<fpage>188</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1002/rth2.12080</pub-id>
<pub-id pub-id-type="pmid">30046721</pub-id>
</element-citation>
</ref>
<ref id="B95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schade</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>R. P.</given-names>
</name>
</person-group>
<article-title>Residual cardiovascular risk—is inflammation the primary cause?</article-title>
<source/>
<italic toggle="yes">World Journal of Cardiovascular Diseases</italic>
<year>2018</year>
<volume>8</volume>
<issue>1</issue>
<fpage>59</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.4236/wjcd.2018.81007</pub-id>
</element-citation>
</ref>
<ref id="B96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>K. V.</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>de Lemos</surname>
<given-names>J. A.</given-names>
</name>
</person-group>
<article-title>Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine</article-title>
<source/>
<italic toggle="yes">Circulation</italic>
<year>2018</year>
<volume>137</volume>
<issue>24</issue>
<fpage>2551</fpage>
<lpage>2553</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.035289</pub-id>
<pub-id pub-id-type="other">2-s2.0-85053926895</pub-id>
<pub-id pub-id-type="pmid">29643058</pub-id>
</element-citation>
</ref>
<ref id="B97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>W. Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>LPA</italic> variants are associated with residual cardiovascular risk in patients receiving statins</article-title>
<source/>
<italic toggle="yes">Circulation</italic>
<year>2018</year>
<volume>138</volume>
<issue>17</issue>
<fpage>1839</fpage>
<lpage>1849</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.031356</pub-id>
<pub-id pub-id-type="other">2-s2.0-85050959915</pub-id>
<pub-id pub-id-type="pmid">29703846</pub-id>
</element-citation>
</ref>
<ref id="B98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schüssler-Fiorenza Rose</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Contrepois</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Moneghetti</surname>
<given-names>K. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A longitudinal big data approach for precision health</article-title>
<source/>
<italic toggle="yes">Nature Medicine</italic>
<year>2019</year>
<volume>25</volume>
<issue>5</issue>
<fpage>792</fpage>
<lpage>804</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-019-0414-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-85065589220</pub-id>
<pub-id pub-id-type="pmid">31068711</pub-id>
</element-citation>
</ref>
<ref id="B99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kronenberg</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Human genetics and the causal role of lipoprotein(a) for various diseases</article-title>
<source/>
<italic toggle="yes">Cardiovascular Drugs and Therapy</italic>
<year>2016</year>
<volume>30</volume>
<issue>1</issue>
<fpage>87</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="doi">10.1007/s10557-016-6648-3</pub-id>
<pub-id pub-id-type="other">2-s2.0-84961112691</pub-id>
<pub-id pub-id-type="pmid">26896185</pub-id>
</element-citation>
</ref>
<ref id="B100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Noureen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kronenberg</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Utermann</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Structure, function, and genetics of lipoprotein(a)</article-title>
<source/>
<italic toggle="yes">Journal of Lipid Research</italic>
<year>2016</year>
<volume>57</volume>
<issue>8</issue>
<fpage>1339</fpage>
<lpage>1359</lpage>
<pub-id pub-id-type="doi">10.1194/jlr.R067314</pub-id>
<pub-id pub-id-type="other">2-s2.0-84982764410</pub-id>
<pub-id pub-id-type="pmid">27074913</pub-id>
</element-citation>
</ref>
<ref id="B101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovacic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bakran</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Genetic susceptibility to atherosclerosis</article-title>
<source/>
<italic toggle="yes">Stroke Research and Treatment</italic>
<year>2012</year>
<volume>2012</volume>
<fpage>5</fpage>
<pub-id pub-id-type="publisher-id">362941</pub-id>
<pub-id pub-id-type="doi">10.1155/2012/362941</pub-id>
<pub-id pub-id-type="other">2-s2.0-84859766579</pub-id>
<pub-id pub-id-type="pmid">22550613</pub-id>
</element-citation>
</ref>
<ref id="B102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McPherson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tybjaerg-Hansen</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Genetics of coronary artery disease</article-title>
<source/>
<italic toggle="yes">Circulation Research</italic>
<year>2016</year>
<volume>118</volume>
<issue>4</issue>
<fpage>564</fpage>
<lpage>578</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306566</pub-id>
<pub-id pub-id-type="other">2-s2.0-84959041610</pub-id>
<pub-id pub-id-type="pmid">26892958</pub-id>
</element-citation>
</ref>
<ref id="B103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sivapalaratnam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Motazacker</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Maiwald</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide association studies in atherosclerosis</article-title>
<source/>
<italic toggle="yes">Current Atherosclerosis Reports</italic>
<year>2011</year>
<volume>13</volume>
<issue>3</issue>
<fpage>225</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1007/s11883-011-0173-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-79955884571</pub-id>
<pub-id pub-id-type="pmid">21369780</pub-id>
</element-citation>
</ref>
<ref id="B104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The roles of TLR gene polymorphisms in atherosclerosis: a systematic review and meta-analysis of 35,317 subjects</article-title>
<source/>
<italic toggle="yes">Scandinavian Journal of Immunology</italic>
<year>2017</year>
<volume>86</volume>
<issue>1</issue>
<fpage>50</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1111/sji.12560</pub-id>
<pub-id pub-id-type="other">2-s2.0-85020541103</pub-id>
<pub-id pub-id-type="pmid">28474755</pub-id>
</element-citation>
</ref>
<ref id="B105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madsen</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Varbo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nordestgaard</surname>
<given-names>B. G.</given-names>
</name>
</person-group>
<article-title>Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies</article-title>
<source/>
<italic toggle="yes">European Heart Journal</italic>
<year>2017</year>
<volume>38</volume>
<issue>32</issue>
<fpage>2478</fpage>
<lpage>2486</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehx163</pub-id>
<pub-id pub-id-type="other">2-s2.0-85028382108</pub-id>
<pub-id pub-id-type="pmid">28419274</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="tab1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Summary of the main endotypes of atherosclerosis [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B84">84</xref>, <xref ref-type="bibr" rid="B93">93</xref>, <xref ref-type="bibr" rid="B99">99</xref>–<xref ref-type="bibr" rid="B105">105</xref>].</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Endotype</th>
<th align="center" colspan="1" rowspan="1">Genetics</th>
<th align="center" colspan="1" rowspan="1">Biomarkers</th>
<th align="center" colspan="1" rowspan="1">Clinical features and comorbid conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">LDL</td>
<td align="center" colspan="1" rowspan="1">LDLR, PCSK9, APOE, APOB-100, SORT1, and ANGPTL3</td>
<td align="center" colspan="1" rowspan="1">Total cholesterol, LDL-C, ApoB, ApoВ-100, ox-LDLs, modified LDL, sdLDL, and PCSK9</td>
<td align="center" colspan="1" rowspan="1">Alzheimer's disease, breast cancer, colon cancer, and prostate cancer</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lp (a)</td>
<td align="center" colspan="1" rowspan="1">LPA</td>
<td align="center" colspan="1" rowspan="1">LP(а) and apo(a) isoforms</td>
<td align="center" colspan="1" rowspan="1">Aortic stenosis and venous thromboembolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hypertension</td>
<td align="center" colspan="1" rowspan="1">ADAMTS7, THBS2, CFDP1, NOX4, EDNRA, PHACTR1, GUCY1A3, CNNM2, CYP17A1, FGF5, and NOS3</td>
<td align="center" colspan="1" rowspan="1">Endothelin, angiotensin, adrenomedullin, natriuretic peptides, von Willebrand factor, cell adhesion molecules, endothelial progenitor cells, endothelial microparticles, NO, and asymmetric dimethylarginine</td>
<td align="center" colspan="1" rowspan="1">Hemorrhagic stroke, chronic kidney disease, atrial fibrillation, vascular dementia, and left ventricular hypertrophy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Inflammation</td>
<td align="center" colspan="1" rowspan="1">MCP-1, M-CSF, VCAM-1, IL-6R, PECAM1, SH2B3, CXCL12, SMAD3, and TLRs-genes</td>
<td align="center" colspan="1" rowspan="1">TNF, IL-1b, IL-6, IL-12, IL-18, IL-23, IFN-g+IL-17+IL-22+TH17 cells, hsCRP, pentraxin-3, sCD40L, VCAM, and ICAM</td>
<td align="center" colspan="1" rowspan="1">Rheumatoid arthritis, inflammatory bowel disease, solid tumors, and psychiatric disorders</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Metabolic</td>
<td align="center" colspan="1" rowspan="1">HNF1A, SH2B3, PPP1R3B, and CTRB1/2</td>
<td align="center" colspan="1" rowspan="1">Blood glucose, blood insulin, C-peptide, glycated hemoglobin, and glycated albumin</td>
<td align="center" colspan="1" rowspan="1">Diabetes mellitus, maturity onset diabetes of the young, hepatic adenoma, psoriasis, Alzheimer's disease, affective disorders, breast cancer, colorectal cancer, and pancreatic cancer</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Comments: EDNRA=endothelin receptor type A; PHACTR1=phosphatase and actin regulator 1; GUCY1A3=guanylate cyclase 1 soluble subunit alpha 1; CNNM2=cyclin and CBS domain divalent metal cation transport mediator 2; CYP17A1=cytochrome P450 family 17 subfamily A member 1; SORT1=sortilin 1; FGF5=fibroblast growth factor 5; HNF1A=hepatocyte nuclear factor 1 homeobox A; SH2B3=SH2B adaptor protein 3; PECAM1=platelet endothelial cell adhesion molecule 1; CXCL12=C-X-C motif ligand 12; ANGPTL3=angiopoietin-like protein 3; PPP1R3B=protein phosphatase 1 regulatory subunit 3B; CTRB1/2=chymotrypsinogen B1; SMAD3=mothers against decapentaplegic homolog 3; NOS3=nitric oxide synthase 3; LDLR=low-density lipoprotein receptor; PCSK9=proprotein convertase subtilisin/kexin type 9; APOB=apolipoprotein B; sdLDL=small dense low-density lipoproteins; ADAMTS=a disintegrin and metalloproteinase with thrombospondin motifs; THBS2=thrombospondin-2; CFDP1=craniofacial development protein 1; NOX4=NADPH oxidase 4; MCP-1=monocyte chemoattractant protein 1; M-CSF=macrophage colony-stimulating factor; VCAM-1=vascular cell adhesion molecule 1; IL-6R=interleukin-6 receptor; HNF1A=hepatocyte nuclear factor 1 homeobox A; TNF=tumor necrosis factor; IL=interleukin; hsCRP=high-sensitivity C-reactive protein; sCD40L=soluble CD40 ligand.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>